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In Vitro Effects of Cyclosporine and FK 506 on the Renal Cortex 
S.J. Prasad, J. McCauley, G. Salama, T.E. Starzl, and SA Murray 
CYCLOSPORINE (CyA) and FK 506 are the effective immunosuppressive agents used in human organ 
transplantation and a variety of autoimmune diseases. 1-3 
The nephrotoxicity of Cy A is well known.4•5 Preliminary 
reports indicate the nephrotoxic nature of FK 506. though 
the clinical significance is yet to be established. especially 
in view of the favorable side effect profile that FK 506 
possesses.6-8 The mechanism of nephrotoxicity of Cy A is 
not clearly established. Direct toxicity on the cell and cell 
membranes. altered prostaglandin synthesis. changes in 
the handling of calcium by the cells. and hemodynamic 
alterations have all been implicated.9 Very little is known 
about the toxicity of FK 506. There is paucity of data on 
the direct effects of Cy A and FK 506 on renal tissue. Here 
we report the in vitro effects of both CyA and FK 506 on 
the calcium sequestration by the microsomes and mito-
chondria of renal cortical tissue. 
MATERIALS AND METHODS 
Adult male. white New Zealand rabbits were killed. The kidneys 
were perfused in situ with HEPES (10 mmollL) and sucrose (0.25 
mol/L) medium (pH 7.35). The kidneys were removed and the 
cortices were dissected and homogeruzed in the same medium (10 
mUg). Mitochondria and microsome were isolated by high speed 
and ultracentrifugation as described. lo and stored under liquid 
nitrogen until they were used for the studies. 
The protein concentration was measured with the Biorad reo 
agent. II The ATPase activity was calculated from the amount of 
the inorganic phosphate released in the presence of the mi-
crosomes (50 ILg protein), ATP (3 mmollLl. and EGTA (I 
mmollLl with or without calcium chloride (2 mmoIlL). Inorganic 
phosphate was measured according to the method of Fiske and 
Subba ROW.12 with 10% ascorbic acid as the reducing agent. 
Calcium m the suspending medium was measured with the 
metailochrome indicator Anenazo Ill.') The calcium concentra-
tion was continuously followed at a wavelength pair of 665 nm and 
685 nm in the dual-wavelength spectrophotometer (Biomedical 
instrumentation, Univenity of Pennsylvania. Johnson Research 
Foundation. Philadelphia. Penn). The effect of I to 10 !J.8/mL of 
either C y A or FK 506 on calcium sequestration was compared to 
the control values obtained in the presence of DMSO (10 ",L). The 
microsomal preparation was unaffected by 1 mmollL NaN). The 
mitochondrial calcium uptake was completely blocked by both 
NaN, (1 mmollLl and FCCP (S /LffioIlL) , thus confirming the 
nature of the microsomal and mitochondrial preparation. The 
tracings from single preparation. done on the same day. are 
presented. At the end of 10 or 20 minutes of calcium uptake. 
A23187 (2 !J.8/mL) was added to release the sequested calcium. 
RESULTS 
There was a dose-dependent decrease in calcium uptake 
by the microsome in the presence of eyA (Fig lA and B). 
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FIg 1. Effect of CyA (A and B) and FK 506 (C and D) on the 
microsomal calcium uptake (A and C) and A23187-induced re-
lease of calcium (8 and D). Concentration of the drug is given 
beside eact1 curve. 
Similarly, there was a dose-dependent decrease in calcium 
release from microsomes following the addition of A23187 
(Fig IB). A significant decrease in calcium uptake and 
release by the ionophore from the microsomes was seen in 
the presence of FK 506 (Fig 2C and D). Higher concentra-
tions of FK 506 (10 ,...wmL) further decreased calcium 
uptake. 
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Fig 2. Effect of eyA (A and B) and FK 506 (C and DJ on 
mitochondrial calcium uptake (A and e) and A23187·induced 
relaase (8 and D). The numbers along each curve represent the 
concentration (p.gImL) of eyA (A and B) and FK 506 (C and OJ. 
In the mitochondria. similar to what occurred in the 
microsome. there was a dose-dependent decrease in the 
calcium sequestration in the presence ofCyA (Fig 2A and 
B) and FK 506 (Fig 2C and 0). Furthermore. both CyA 
and FK 506 caused a dose-dependent decrease in A23187 
releasable calcium. The effect of FK 506 was seen only at 
very high concentrations of the drug. 
There was two- to three-fold stimulation of microsomal 
ATPase activity in the presence of calcium. This is sug-
gestive of the specific nature of the enzyme studied. At the 
concentrations of the drugs used (l to 10 ~miFK neither 
Cy A nor FK 506 had an effect on calcium-stimulated 
ATPase activity. 
In the experiments in which mitochondria and mi-
crosomes were coincubated with the drug. kAlme~ and 
microsomes provided the drug metabolizing activity. Cy A 
inhibited the calcium uptake. kAame~ (0.1 mmoUL) itself 
had no effect on the calcium uptake. but reversed the effect 
of 5 /-L8 of Cy A. OIT 1 mmolfL added 10 minutes into the 
incubation in the presence of Cy A restored the calcium-
sequestrating ability. Both GSH (l mmolfL) and OIT (l 
mmolfL) were effective in preventing the inhibitory effect 
of the Cy A. FK 506. at a concentration of 5.0 ~K had only 
minimal effect on calcium sequestration. Addition of 
kAame~ in the presence of FK 506 (0.1 mmolfL) inhib-
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ited calcium' sequestration' significantly. This was pre-
vented by GSH and OIT (1 mmoUL). 
DISCUSSION 
The results indicate that Cy A, at concentrations that are 
clinically encountered, is inhibitory to calcium sequestra-
tion by both the microsome and the mitochondria. isolated 
from the renal cortex. FK 506 also inhibited the calcium 
sequestration by these organelles. however, at concentra-
tions that are much higher than the therapeutic levels 
reported.7•8 It is also evident that mitochondria are rela-
tively resistant to the effects of the Cy A and FK 506. thus, 
concentrations of Cy A and FK 506 that are inhibitory to 
only the endoplasmic reticulum, sparing the mitochondria. 
would be expected to alter the distribution of the intracel-
lular stores of the calcium. This is consistent with the 
findings of Zidek and Neuman. 14 in permeabilized human 
neutrophils incubated in the presence of the Cy A. In 
isolated rat hepatocytes. CyA (10 ~miF was shown to 
increase calcium flux across the plasma membrane and 
increase the cellular calcium content. IS Another important 
finding is the effect of metabolic transformation of these 
drugs on their ability to inhibit the calcium sequestration 
by the cellular organelles. The data clearly indicate con-
version ofCyA to an inactive metabolite (S) and FK 506 to 
an active metabolite in the presence of the microsomal 
drug-metabolizing system. Further. a critical role for sulf-
hydryl groups is suggested by the protective effects of the 
sulfhydryl reagents on Cy A and the FK 506 inhibition of 
the calcium sequestration by the cellular organelles. 
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